There are important changes for urologists to note in the newly published update of the AUA’s policy statement on multiparametric magnetic resonance imaging (MRI) for diagnosing, staging and managing prostate cancer, according to policy statement co-author Marc A. Bjurlin, DO, MSc.
This update to the original statement, published October 2017, is now endorsed by both the AUA and the Society of Abdominal Radiology, according to Dr. Bjurlin, of Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.
“We have several more experts on our panel from the radiology community who contributed, and this was new from the very first policy statement. The second major update we made is there is now sufficient data to support the use of prostate MRI in all men before their initial prostate biopsy when the MRI is of sufficient quality. Our initial statement didn’t have enough data to support that indication,” Dr. Bjurlin told Urology Times. The updated statement was published online ahead of print in the Journal of Urology (Oct. 23, 2019).
In essence, research supports use of a quality prostate MRI before an initial biopsy in men at risk of harboring prostate cancer and in men with a rising PSA after an initial negative standard prostate biopsy, the expert panel wrote.